Clinical Pharmacology of Potassium Channel Openers

Pharmacology & Toxicology

Volumn 70, Issue 4, 1992, Pages 244-254

  Andersson, Karl‐Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CROMAKALIM; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ASTHMA; BIOAVAILABILITY; BLADDER INSTABILITY; BLOOD FLOW; BRONCHOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; DOG; DRUG METABOLISM; EDEMA; ENANTIOMER; FLUSHING; GUINEA PIG; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MEMBRANE POTENTIAL; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RABBIT; SHORT SURVEY; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; CARDIOVASCULAR SYSTEM; CROMAKALIM; GUANIDINES; HUMAN; NIACINAMIDE; NICORANDIL; PINACIDIL; POTASSIUM CHANNELS; PYRROLES; RESPIRATORY SYSTEM;

ANGINA; ANIMALIA; CANIS FAMILIARIS; CAVIA PORCELLUS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0026562018     PISSN: 09019928     EISSN: 16000773     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1992.tb00466.x     Document Type: Article

References (141)

1. Effect of nicorandil on coronary spasm
2. Electromyographic studies of bronchial smooth muscle in bronchial asthma
3. Electrical and mechanical effects of BRL 34915 in guinea‐pig isolated trachealis
4. Mechanisms of pinacidil‐induced vasodilatation
5. Current concepts in the treatment of disorders of micturition
6. Effects of pinacidil on bladder muscle
7. 2+ antagonists or hydralazine, in an animal model of occlusive arterial disease
8. Evaluation of the potassium channel activator cromakalim (BRL 34915) as a bronchodilator in the guinea‐pig: comparison with nifedipine
9. Activation of ATP‐sensitive K channels in heart cells by pinacidil: dependence on ATP
10. Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C‐ and N‐oxidative polymorphisms
11. Cromakalim, a potassium channel activator, inhibits histamine induced bronchoconstriction in healthy volunteers
12. The action of a potassium channel activator, BRL 38227 (lemakalim), on human airway smooth muscle
13. Potassium channels and airway function: new therapeutic prospects
14. Comparison of the inhibitory effects of BRL 34915 and nifedipine on noradrenaline‐ and KCl‐induced contractions in rabbit aorta
15. Analysis of the inhibitory action of BRL 34915 on the responses to noradrenaline in rabbit aorta
16. Effects of the potassium channel activator, BRL 34915, on the action potential characteristics of canine cardiac Purkinje fibers
17. Effects of cromakalim on neurally‐mediated responses of guineapig tracheal smooth muscle
18. Comparison of the effects of cromakalim, a potassium conductance enhancer, and nimodipine, a calcium antagonist, on 5‐hydroxytryptamine responses in a variety of vascular smooth muscle preparations
19. Double‐blind comparator trials with pinacidil, a potassium channel opener
20. A controlled single‐dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris
21. Pharmacokinetics of cromakalim – a new antihypertensive agent, in patients with mild essential hypertension
22. e sensitivity
23. Reversal of induced airway hyper‐reactivity by potassium channel openers: PCO 400 and cromakalim
24. Profibrillatory actions of pinacidil in a conscious canine model of sudden coronary death
25. Antihypertensive and haemodynamic properties of the potassium channel activating (—)enantiomer of cromakalim in animal models
26. + channels protect the myocardium against ischemia/reperfusion damage
27. The pharmacology of potassium channels and their therapeutical potential
28. + channel opener cromakalim on the rabbit aorta – comparison with calcium antagonist isradipine
29. The pharmacokinetics of cromakalim, BRL 34915, a new antihypertensive agent, in healthy male subjects
30. Control of human airway smooth muscle: in vitro studies
31. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects
32. Potassium channel activation in the smooth muscle cell membrane – a new mechanism of action in antihypertensive treatment – early clinical results with BRL 34915
33. Comparison of the effects of several potassium‐channel openers on rat bladder and rat portal vein in vitro
34. Potassium channel openers and vascular smooth muscle relaxation
35. + channel openers
36. Metabolism of the new antihypertensive agent pinacidil in rat, dog and man
37. Actions of pinacidil on calcium release in single vascular muscle cells of rat veins
38. + channels in the heart
39. The effect of cromakalim on the smooth muscle of the guinea‐pig urinary bladder
40. The effects of cromakalim on the detrusor muscle of human and pig urinary bladder
41. The action of pinacidil in the isolated human bladder
42. Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers
43. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension
44. Pharmacokinetics of nicorandil
45. An electrophysiological investigation of the mechanism of action of BRL 34915 on the guinea‐pig bladder
46. Potassium channel blockers and the effects of cromakalim on the smooth muscle of the guinea‐pig bladder
47. + channel openers prevent epilepsy induced by the bee venom peptide MCD
48. + channel openers decrease seizures in genetically epileptic rats
49. Effects of SR 44866, a potassium channel opener, on action potentials of rabbit, guinea pig and human heart fibers
50. Effects of cromakalim and pinacidil on large epicardial and small coronary arteries in conscious dogs
51. Effect of pinacidil upon penile erectile tissue, in vitro and in vivo
52. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension
53. Is the cardiovascular profile of BRL 34915 characteristic of potassium channel activators?
54. Cardiohemodynamic effects of cromakalim and pinacidil, potassium‐channel openers, in the dog, special reference to venous return
55. Effects of nicorandil on coronary circulation and myocardial ischemia
56. Anti‐ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide
57. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides
58. Pharmacological profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs
59. Nicorandil improves postischemic contractile function independently of direct myocardial effects
60. Possible cellular mechanism for cerebral vasospasm after experimental subarachnoid hemorrhage in the dog
61. Effects of pinacidil on detrusor instability in men with outlet obstruction
62. Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL34915 and its enantiomers
63. +‐channel openers for relaxation of isolated penile erectile tissue from rabbit
64. Effects of pinacidil on isolated human corpus cavernosum penis
65. A potassium channel activator modulates both excitatory non‐choniergic and cholinergic neurotransmission in guinea pig airways
66. Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamite
67. +‐treated intact, and in β‐escin‐treated skinned smooth muscle of the rabbit mesenteric artery
68. Vasodilating and hypotensive properties of KRN2391
69. Mechanisms of vasodilatation induced by potassium‐channel activators
70. + loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea
71. Effects of pinacidil on serotonin‐induced contractions and cyclic nucleotide levels in isolated rat aortae: comparison with nitroglycerin, minoxidil, and hydralazine
72. Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug
73. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism
74. Pharmacology and therapeutic effects of nicorandil
75. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris
76. 86Rb flux studies in rabbit isolated vascular smooth muscle
77. Analysis of cromakalim‐, pinacidil‐, and nicorandil‐induced relaxation of the 5‐hydroxytryptamine precontracted rat isolated basilar artery
78. Nimodipine – a review of its pharmacodynamic and pharmacodynamic properties, and therapeutic potential in cerebrovascular disease
79. Electrophysiological mechanisms of minoxidil sulphate‐induced vasodilatation of rabbit portal vein
80. +‐channel activator cromakalim in man
81. Electrophysiological and antiarrhythmic effects of the K‐channel opener, BRL 34915, in cardiac Purkinje fibers
82. Effects of pinacidil and cromakalim (BRL 34915) on bladder function in rats with detrusor instability
83. Effects of cromakalim (BRL 34915) and pinacidil on normal and hypertrophied rat detrusor in vitro
84. Calcium channel currents in isolated cells from human bronchus
85. Potassium channel opening properties of a novel compound, NIP‐121, cromakalim and nicorandil in rat aorta and portal vein
86. Possible involvement of ATP‐sensitive channels in the relaxant response of dog middle cerebral artery to cromakalim
87. Accumulation of pinacidil N‐oxide during chronic treatment with pinacidil
88. Calcium‐activated potassium channels in canine airway smooth muscle
89. Cromakalim and pinacidil dilate small mesenteric arteries but not small cerebral arteries
90. Characterization of responses to cromakalim and pinacidil in smooth and cardiac muscle by use of selective antagonists
91. Exercise capacity after single and twice‐daily doses of nicorandil in chronic stable angina pectoris
92. + permeability
93. + channel‐dependent as well as independent components of pinacidil‐induced vasodilation
94. Cromakalim‐induced relaxation of guinea pig isolated trachealis: antagonism by gliben‐clamide and by phentolamine
95. 2+ levels
96. Pinacidil inhibits neuromuscular transmission indirectly in the guinea‐pig and rabbit mesenteric arteries
97. Effect of pinacidil on sympathetic neuroeffector transmission in rabbit blood vessels
98. The action of diazoxide and minoxidil sulphate on rat blood vessels: a comparison with cromakalim
99. Effects of pinacidil on guinea‐pig airway smooth muscle contracted by asthma mediators
100. Glibenclamide blocks the relaxant action of pinacidil and cromakalim in airway smooth muscle
101. Cardioprotective effects of KRN2391 on ischemic dysfunction in perfused rat heart
102. An analysis of the nitrate‐like and K channel opening actions of KRN2391 in canine coronary arterial smooth muscle
103. + conductance of heart cell membrane by BRL 34915
104. Randomised, double blind, placebo controlled, crossover (RDBPCC) study of a potassium channel activator (KCA) in morning dipping
105. Preclinical pharmacology of Ro 31‐6930, a new potassium channel opener
106. Evaluation of the bronchodilator properties of RO 31‐6930, a novel potassium channel opener, in the guinea‐pig
107. Comparison of cromakalim‐induced relaxation of potassium precontracted rabbit, cat, and rat isolated cerebral arteries
108. Cerebral vasospasm: acute proliferative vasculopathy? 2. Morphology
109. + channel activators, RP 52891, cromakalim, and diazoxide, on the plasma insulin level, plasma renin activity, and blood pressure in rats
110. The cardiovascular effects of SDZ PCO 400 in vivo: comparison with cromakalim
111. +‐channels
112. BRL 34915 ameliorates oxygen supply in ischemic myocardium by a simultaneous enhancement of coronary blood flow and a reduction of myocardial function
113. +‐channel: a comparison with nifedipine
114. Aerosol steroids as primary treatment of mild asthma
115. Agonistes potassiques: profil vasodilatateur régional chez le rat
116. + channel openers, a class of drugs with vasorelaxant and cardioprotective properties
117. Potassium channel modulators: scientific applications and therapeutic promise
118. Beneficial effects of pinacidil on blood lipids: comparisons with prazosin and placebo in patients with hypertension
119. Effects of pinacidil on myocardial blood flow and infarct size after acute left anterior descending coronary artery occlusion and reperfusion in awake dogs with and without a coexisting left circumflex coronary artery stenosis
120. + conductance in cardiac muscle
121. Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915)
122. Modification by glibenclamide of the electrophysiological consequences of myocardial ischemia in dogs and rabbits
123. Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity
124. Hemodynamic action of nicorandil in chronic congestive heart failure
125. The potassium channel opening action of pinacidil; studies using biochemical, ion flux and microelectrode techniques
126. + current activated by pinacidil
127. + channels in arterial smooth muscle
128. Chiral recognition of pinacidil and its 3‐pyridyl isomer by canine cardiac and smooth muscle: antagonism by sulfonylureas
129. Coronary vasodilatory action after nicorandil: a quantitative angiographic study
130. Nicorandil as a hybrid between nitrates and potassium channel activators
131. Acute haemodynamic effects of cromakalim in patients with angina pectoris
132. Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers
133. The effects of pinacidil and tolbutamide in feline pial arteries in situ
134. The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers
135. +‐channel openers cromakalim and minoxidil sulphate on vascular smooth muscle
136. Attenuation of nocturnal asthma by cromakalim
137. Attempts at prevention or treatment of intracranial spasm: an update
138. Cytoplasmic calcium and the relaxation of canine coronary arterial muscle produced by cromakalim, pinacidil and nicorandil
139. Nicorandil increases coronary blood flow predominantly by K‐channel opening mechanism
140. Reactivity of rabbit basilar artery to alterations in extracellular potassium and calcium after subarachnoid hemorrhage